These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 23087181)

  • 21. Arthritis development in patients with arthralgia is strongly associated with anti-citrullinated protein antibody status: a prospective cohort study.
    Bos WH; Wolbink GJ; Boers M; Tijhuis GJ; de Vries N; van der Horst-Bruinsma IE; Tak PP; van de Stadt RJ; van der Laken CJ; Dijkmans BA; van Schaardenburg D
    Ann Rheum Dis; 2010 Mar; 69(3):490-4. PubMed ID: 19363023
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Autoantibodies in early seropositive rheumatoid arthritis, before and during disease modifying antirheumatic drug treatment.
    Paulus HE; Wiesner J; Bulpitt KJ; Patnaik M; Law J; Park GS; Wong WK
    J Rheumatol; 2002 Dec; 29(12):2513-20. PubMed ID: 12465144
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Inflammation and autoantibody markers identify rheumatoid arthritis patients with enhanced clinical benefit following rituximab treatment.
    Lal P; Su Z; Holweg CT; Silverman GJ; Schwartzman S; Kelman A; Read S; Spaniolo G; Monroe JG; Behrens TW; Townsend MJ
    Arthritis Rheum; 2011 Dec; 63(12):3681-91. PubMed ID: 22127691
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A prospective cohort study of 14-3-3η in ACPA and/or RF-positive patients with arthralgia.
    van Beers-Tas MH; Marotta A; Boers M; Maksymowych WP; van Schaardenburg D
    Arthritis Res Ther; 2016 Apr; 18():76. PubMed ID: 27037016
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Rheumatoid factor positivity rather than anti-CCP positivity, a lower disability and a lower number of anti-TNF agents failed are associated with response to rituximab in rheumatoid arthritis.
    Quartuccio L; Fabris M; Salvin S; Atzeni F; Saracco M; Benucci M; Cimmino M; Morassi P; Masolini P; Pellerito R; Cutolo M; Puttini PS; De Vita S
    Rheumatology (Oxford); 2009 Dec; 48(12):1557-9. PubMed ID: 19789202
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Blockade of tumour necrosis factor {alpha} significantly alters the serum level of IgG- and IgA-rheumatoid factor in patients with rheumatoid arthritis.
    Yazdani-Biuki B; Stadlmaier E; Mulabecirovic A; Brezinschek R; Tilz G; Demel U; Mueller T; Brickmann K; Graninger WB; Brezinschek HP
    Ann Rheum Dis; 2005 Aug; 64(8):1224-6. PubMed ID: 16014683
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Association of rheumatoid arthritis treatment response and disease duration with declines in serum levels of IgM rheumatoid factor and anti-cyclic citrullinated peptide antibody.
    Mikuls TR; O'Dell JR; Stoner JA; Parrish LA; Arend WP; Norris JM; Holers VM
    Arthritis Rheum; 2004 Dec; 50(12):3776-82. PubMed ID: 15593224
    [TBL] [Abstract][Full Text] [Related]  

  • 28. IgM-rheumatoid factor, anti-cyclic citrullinated peptide, and anti-citrullinated human fibrinogen antibodies decrease during treatment with the tumor necrosis factor blocker infliximab in patients with rheumatoid arthritis.
    Vis M; Bos WH; Wolbink G; Voskuyl AE; Twisk JW; Van de Stadt R; Hamann D; Dijkmans BA; Lems WF
    J Rheumatol; 2008 Mar; 35(3):425-8. PubMed ID: 18322974
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Abatacept reduces levels of switched memory B cells, autoantibodies, and immunoglobulins in patients with rheumatoid arthritis.
    Scarsi M; Paolini L; Ricotta D; Pedrini A; Piantoni S; Caimi L; Tincani A; Airò P
    J Rheumatol; 2014 Apr; 41(4):666-72. PubMed ID: 24584924
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Circulating anti-citrullinated peptide antibodies, cytokines and genotype as biomarkers of response to disease-modifying antirheumatic drug therapy in early rheumatoid arthritis.
    Ally MM; Hodkinson B; Meyer PW; Musenge E; Tintinger GR; Tikly M; Anderson R
    BMC Musculoskelet Disord; 2015 May; 16():130. PubMed ID: 26021985
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Decrease of disease activity under ineffective therapy in DMARD-naive patients with early rheumatoid arthritis: role of antibody profiles and carriage of the HLA shared epitope in predicting decrease of disease activity.
    Vander Cruyssen B; Miltenburg AM; Van den Bosch F; Houbiers JG; Wittoek R; Boots AM; De Keyser F
    J Rheumatol; 2007 Oct; 34(10):1992-6. PubMed ID: 17924607
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Repeat serological testing for anti-citrullinated peptide antibody after commencement of therapy is not helpful in patients with seronegative rheumatoid arthritis.
    Reid AB; Wiese M; McWilliams L; Metcalf R; Hall C; Lee A; Hill C; Wechalekar M; Cleland L; Proudman SM
    Intern Med J; 2020 Jul; 50(7):818-822. PubMed ID: 32656986
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Serologic changes following B lymphocyte depletion therapy for rheumatoid arthritis.
    Cambridge G; Leandro MJ; Edwards JC; Ehrenstein MR; Salden M; Bodman-Smith M; Webster AD
    Arthritis Rheum; 2003 Aug; 48(8):2146-54. PubMed ID: 12905467
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prevalence of and predictive factors for sustained disease-modifying antirheumatic drug-free remission in rheumatoid arthritis: results from two large early arthritis cohorts.
    van der Woude D; Young A; Jayakumar K; Mertens BJ; Toes RE; van der Heijde D; Huizinga TW; van der Helm-van Mil AH
    Arthritis Rheum; 2009 Aug; 60(8):2262-71. PubMed ID: 19644846
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Antibodies against mutated citrullinated vimentin are a better predictor of disease activity at 24 months in early rheumatoid arthritis than antibodies against cyclic citrullinated peptides.
    Innala L; Kokkonen H; Eriksson C; Jidell E; Berglin E; Dahlqvst SR
    J Rheumatol; 2008 Jun; 35(6):1002-8. PubMed ID: 18398946
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Changes in macrophage function after rituximab treatment in patients with rheumatoid arthritis.
    Toubi E; Kessel A; Slobodin G; Boulman N; Pavlotzky E; Zisman D; Rozenbaum M; Rosner I
    Ann Rheum Dis; 2007 Jun; 66(6):818-20. PubMed ID: 17148544
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The association of treatment response and joint damage with ACPA-status in recent-onset RA: a subanalysis of the 8-year follow-up of the BeSt study.
    van den Broek M; Dirven L; Klarenbeek NB; Molenaar TH; Han KH; Kerstens PJ; Huizinga TW; Dijkmans BA; Allaart CF
    Ann Rheum Dis; 2012 Feb; 71(2):245-8. PubMed ID: 22110122
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Contribution of PTPN22 1858T, TNFRII 196R and HLA-shared epitope alleles with rheumatoid factor and anti-citrullinated protein antibodies to very early rheumatoid arthritis diagnosis.
    Goëb V; Dieudé P; Daveau R; Thomas-L'otellier M; Jouen F; Hau F; Boumier P; Tron F; Gilbert D; Fardellone P; Cornélis F; Le Loët X; Vittecoq O
    Rheumatology (Oxford); 2008 Aug; 47(8):1208-12. PubMed ID: 18535030
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prevalence of anti cyclic citrullinated peptide antibodies in Malaysian rheumatoid arthritis patients and its correlation with disease activity.
    Sockalingam S; Khuan CS; Sthaneshwar P
    Int J Rheum Dis; 2009 Sep; 12(3):211-5. PubMed ID: 20374348
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Absent "Window of Opportunity" in smokers with short disease duration. Data from BARFOT, a multicenter study of early rheumatoid arthritis.
    Söderlin MK; Bergman S;
    J Rheumatol; 2011 Oct; 38(10):2160-8. PubMed ID: 21807778
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.